👉Are you already using apixaban and rivaroxaban in NVAF patients with obesity? Now we have safety and efficacy data! Check it out here⬇️
https://t.co/wN3AiRhyaZ
#WhatsNewWednesday@PharmacoJournal
Thanks to everyone who participated in #EMPRx22 ! We're happy to announce that the recordings and slides are now available for everyone on the website at https://t.co/96DeKauO17
Stay tuned for more important info in the coming weeks
#TwitteRx#FOAM#EMRx
This week's highly anticipated #TeachingTuesday from @BobbiePharmD (and mentor @deepdev511) explores the duration of DAPT after PCI. What patient factors do you consider when recommending DAPT durations in your clinical practice? Let us know! #CardioTwitter
Dear Pharmacists esp CC & ID bookmark this 🆕💥💥 #IJAA @ischemo
Recommended Antibiotic Dosage Regimens in Critically Ill Patients with Augmented Renal Clearance: A Systematic Review
🌟ARC Abx Doses 🌟
#IDTwitter#medtwitter#TwitteRx#MedEd
https://t.co/K5Y5Aqv1xW
📄🤓👾💊🦠🔬📖
Updated my antibiotic cheat sheet to being a “bugs & drugs cheat sheet”
📲 https://t.co/Hg3Rk2cX2z
💬 Any suggestions for additional updates are 😃 welcomed. #IDtwitter#TwitteRx
Confused by someone labeled "immunocompromised" and their infection risks? Same. So with guidance of our ID Mentors @PrathitKulkarni, @Cortes_Penfield, & @transplantID - @KatieBedardMD, Charmaine Mutucumarana and I created an Infections in Immunocompromised Hosts Schema
Pharmacy residents! Interested in a career in #infectiousdiseases? Learn more about our PGY2 ID residency program here: https://t.co/pYvEPNEztl! #PharmRes
In case you don't have the time to read the paper ahead of tonight, don't worry we have you covered. Checkout this🔥visual abstract and join us at 9pm! COVID19-free discussions guaranteed 😊